RTP Mobile Logo
Newly Approved Agents for Patients with Metastatic Urothelial Bladder Carcinoma Who Experience Disease Progression on Immune Checkpoint Inhibitor Therapy (Video Program)
Released January 2021

Featuring a roundtable discussion with Dr Elizabeth R Plimack, Dr Jonathan E Rosenberg, Mr Andrew Ruplin and Ms Cristina Salabao. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This activity has been designed to meet the educational needs of registered nurses, nurse practitioners, clinical nurse specialists and pharmacists involved in the treatment of bladder cancer.

    PURPOSE STATEMENT
    By providing information on the latest research developments in the context of expert perspectives, this activity will assist oncology nurses, nurse practitioners, clinical nurse specialists and pharmacists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with bladder cancer.

    LEARNING OBJECTIVES

    • Recognize how biologic and patient-specific factors influence the selection and sequencing of treatment for patients with metastatic urothelial bladder carcinoma (mUBC) who experience disease progression on immune checkpoint inhibitor therapy.
    • Recall the mechanism of action of and pivotal clinical trial findings with enfortumab vedotin for previously treated locally advanced or metastatic UBC, and identify patients for whom treatment with this novel agent would be appropriate.
    • Recognize the FDA approval of erdafitinib for patients with advanced UBC and susceptible FGFR3 or FGFR2 genetic alterations whose disease has progressed during or after at least 1 line of platinum-containing chemotherapy, and determine how this agent may be appropriately integrated into clinical practice.
    • Educate patients about the unique side effects and pharmaceutical considerations associated with enfortumab vedotin and with erdafitinib, and develop strategies to prevent, reduce or manage toxicities.
    • Review clinical trial data leading to the recent FDA approval of the anti-PD-L1 antibody avelumab as maintenance therapy after response to first-line platinum-based chemotherapy for patients with mUBC, and incorporate this novel strategy into management algorithms.
    • Identify opportunities to enhance the collaborative role of oncology nurses, nurse practitioners and specialty pharmacists in the comprehensive biopsychosocial care of patients with mUBC to optimize clinical and quality-of-life outcomes.

    ACCREDITATION STATEMENT
    Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

    The University of Texas at Austin College of Pharmacy Continuing Education provided the ACPE accreditation for this course. The University of Texas at Austin College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

    CREDIT DESIGNATION STATEMENTS
    Audio Program: This educational activity for 2.5 contact hours is provided by RTP during the period of January 2021 through January 2022.
    This activity is awarded 2.5 ANCC pharmacotherapeutic contact hours.

    Video Program: This educational activity for 2.5 contact hours is provided by RTP during the period of January 2021 through January 2022.
    This activity is awarded 2.5 ANCC pharmacotherapeutic contact hours.

    ACPE#: 0067-9999-21-013-H01-P
    Activity type: Knowledge
    There is no fee to access this program.

    ONCC/ILNA CERTIFICATION INFORMATION
    The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. To review certification qualifications please visit ResearchToPractice.com/UBCNovelAgents20/ILNA.

    ONCC review is only for designating content to be used for ILNA points and is not for CNE accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

    FOR SUCCESSFUL COMPLETION
    To receive credit, participants should read the learning objectives and faculty disclosures, listen to the MP3s or watch the videos, review the downloadable slide set, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form.

    Audio Program: ResearchToPractice.com/UBCNovelAgents20.
    Audio NCPD Assessment: ResearchToPractice.com/UBCNovelAgents20/CNE.
    Audio PharmD Assessment: ResearchToPractice.com/UBCNovelAgents20/ACPE.

    Video Program: ResearchToPractice.com/UBCNovelAgents20/Video.
    Video NCPD Assessment: ResearchToPractice.com/UBCNovelAgents20/Video/CNE.
    Video PharmD Assessment: ResearchToPractice.com/UBCNovelAgents20/Video/ACPE.

    CONTENT VALIDATION AND DISCLOSURES
    RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of NCPD activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Elizabeth R Plimack, MD, MS
    Chief, Division of Genitourinary Medical Oncology
    Director, Genitourinary Clinical Research
    Professor, Department of Hematology/Oncology
    Fox Chase Cancer Center
    Temple Health
    Philadelphia, Pennsylvania

    Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP, Infinity Pharmaceuticals Inc, Pfizer Inc; Grants for Clinical Research: Astellas, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Merck; Scientific Advisor: Genentech, a member of the Roche Group, Merck, Seagen Inc.

    Jonathan E Rosenberg, MD
    Chief, Genitourinary Medical Oncology Service
    Division of Solid Tumor Oncology
    Enno W Ercklentz Chair
    Memorial Sloan Kettering Cancer Center
    New York, New York

    Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, GlaxoSmithKline, Janssen Biotech Inc, Merck, Mirati Therapeutics, Seagen Inc; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Genentech, a member of the Roche Group, QED Therapeutics, Seagen Inc; Data and Safety Monitoring Board/Committee: Rainier Therapeutics.

    Andrew Ruplin, PharmD
    Oncology Clinical Pharmacist, General Oncology
    Clinical Instructor, University of Washington School of Pharmacy
    Seattle Cancer Care Alliance
    University of Washington Medical Center
    Seattle, Washington

    No financial interests or affiliations to disclose.

    Cristina Salabao, MSN, FNP-C
    Nurse Practitioner
    The Lank Center for Genitourinary Oncology
    Dana-Farber Cancer Institute
    Boston, Massachusetts

    No financial interests or affiliations to disclose.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME/NCPD activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seagen Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc.

    RTP NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by an educational grant from Astellas and Seagen Inc.

    Release date: January 2021
    Expiration date: January 2022

    There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

Acknowledge and close

Watch video
(WIFI is recommended for best performance):

First-Line Systemic Therapy for Patients with Metastatic Urothelial Bladder Carcinoma (mUBC)

Enfortumab Vedotin for Patients with Advanced UBC

Role of Erdafitinib in the Treatment of Advanced UBC

Novel Agents and Approaches for Patients with mUBC

Management of mUBC in the COVID-19 Era

Additional links